Sedivention Raises €2.9 Million to Tackle Obesity

Sedivention, a Germany-based medtech startup, has announced the closing of a €2.9 million seed funding round. The operation was led by bmp Ventures and IBG funds, with participation from the strategic investment arm of a global medtech company, High-Tech Gründerfonds (HTGF), superangels, and Cambridge Ventures. This capital is earmarked to support the development of a new solution for obesity, a chronic condition projected to affect over one billion people globally in the coming years.

Obesity represents a complex health challenge, with existing treatment options often presenting significant limitations. Current therapies, including bariatric surgery and drug treatments, are frequently characterized by invasiveness, high costs, or the need for long-term dependency, making it difficult for many patients to find an effective and sustainable solution.

A Minimally Invasive Cryoablation-Based Therapy

Sedivention's approach stands out for its minimally invasive nature and its one-time outpatient therapy. The procedure is based on targeted cryoablation, delivered via a specially designed balloon catheter, similar to that used in a gastroscopy. This technique uses cold to selectively interrupt hunger-related signals in the vagus nerve.

The aim is to address the underlying physiological mechanisms of obesity, enabling sustained appetite reduction without recourse to complex surgical interventions, implants, or continuous drug therapies. Dr. Ute Nollert, founder and Chief Medical Officer of Sedivention, emphasized that obesity is a chronic disease requiring clinically effective yet minimally invasive treatments capable of addressing the dysregulation of hunger and satiety.

Next Steps: Clinical Development and Market Entry

A functional prototype of the technology has already been developed and successfully tested. The new funds will enable Sedivention to accelerate product development, generate initial clinical data through a first-in-human study, and prepare for subsequent regulatory and market entry steps. This represents a crucial phase for the validation and commercialization of the therapy.

In the long term, Sedivention aims to replace highly invasive surgical procedures with outpatient interventional treatments. This vision could significantly improve access to effective care for a large segment of the population affected by obesity, offering a less burdensome and more accessible alternative.

The Landscape of MedTech Innovations

The MedTech sector continues to be a fertile ground for innovation, with a growing focus on solutions that enhance treatment efficacy while reducing invasiveness and patient recovery times. Investments like the one received by Sedivention reflect market demand for therapies that can offer lasting benefits without the compromises associated with traditional procedures.

While AI-RADAR's scope primarily focuses on LLM technologies and artificial intelligence infrastructure, it is important to note that innovation in adjacent sectors, such as MedTech, often leverages advanced research and development methodologies. The pursuit of one-time and minimally invasive solutions for chronic diseases is a significant trend, aiming to optimize the TCO for healthcare systems and improve patients' quality of life.